Michele Johnson, MD
Obstetrics & Gynecology · Louisville, KYNPI 1942396551
Payments from drug & device makers
What this record shows
Intuitive Surgical accounts for 64.2% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2024 at $9,883 and has fallen 91.2% since, to $866 in 2025. Among obstetrics & gynecology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $68.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- AbbVie$840
- Baxter Healthcare$526
- Aspira Women's Health Inc$412
- Astellas Pharma US Inc$401
- Mayne Pharma Commercial LLC$352
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,41840%
- Education$8,10060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $8,681 |
| AbbVie(2 entities) | 35 | $840 |
| Baxter Healthcare | 6 | $526 |
| Aspira Women's Health Inc | 10 | $412 |
| Astellas Pharma US Inc | 19 | $401 |
| Mayne Pharma Commercial LLC | 20 | $352 |
| Biogen | 11 | $272 |
| Hologic Sales And Service, LLC | 6 | $245 |
| Coopersurgical, Inc. | 2 | $222 |
| Gynesonics, Inc. | 1 | $143 |
| Radius Health, Inc. | 3 | $128 |
| Exeltis, USA Inc. | 8 | $126 |
| Therapeuticsmd, Inc. | 8 | $104 |
| Myovant Sciences Inc. | 6 | $98 |
| Amgen | 6 | $90 |
| Sumitomo Pharma America, Inc. | 4 | $69 |
| Lupin Inc. | 5 | $66 |
| Astellas Pharma Global Development | 1 | $65 |
| Evofem Biosciences, Inc. | 3 | $64 |
| Shield Therapeutics Inc | 4 | $63 |
| Avion Pharmaceuticals | 4 | $52 |
| Novo Nordisk | 3 | $51 |
| Bayer | 3 | $47 |
| Millicent US Inc | 3 | $45 |
| Channel Medsystems, Inc. | 1 | $36 |
| Merck | 2 | $35 |
| Pfizer | 2 | $34 |
| Organon | 3 | $30 |
| Exact Sciences | 2 | $29 |
| Abbott | 1 | $24 |
| Octapharma USA, Inc. | 1 | $23 |
| Bracco Diagnostics Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Virtus Pharmaceuticals LLC | 1 | $18 |
| Scynexis, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Meditrina | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,518 in reported general payments places this provider in the 95th percentile of 474 obstetrics & gynecology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 12 | $30,985 |
| MyrbetriqMirabegron | 27 | $23,122 |
| GemtesaVibegron | 12 | $13,505 |
| Estradiol | 67 | $10,798 |
| Estradiol (Twice Weekly)Estradiol | 25 | $3,075 |
| ProgesteroneProgesterone, Micronized | 24 | $740 |
| ValacyclovirValacyclovir Hcl | 18 | $522 |
| Raloxifene Hcl | 22 | $493 |
| Clobetasol Propionate | 20 | $407 |
| Ibandronate Sodium | 12 | $313 |
| Alendronate Sodium | 23 | $117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $128 | $30,98512 claims |
| Astellas Pharma US IncMyrbetriq | $401 | $23,12227 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $69 | $13,50512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 obstetrics & gynecology providers in Kentucky.
Other obstetrics & gynecology in Louisville
- Resad PasicLouisville$39K
- Bradley YoukilisLouisville$29K
- Gigi GirardLouisville$23K
- Tanya FranklinLouisville$15K
- Megan CestaLouisville$12K
- Linda McClainLouisville$11K
- Kristi HorlanderLouisville$11K
- Kristin BianchiLouisville$11K
- Margarita TerrassaLouisville$10K
- Ashlee BerginLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.